Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Encephalic proteolytic products of compound Piracetam and its preparation

A cerebroprotein hydrolysate, compound piracetam technology, applied in the directions of pill delivery, drug combination, pharmaceutical formulation, etc., can solve the problems of slow curative effect, low cure rate of therapeutic drugs, inability to cure, and achieve the improvement and enhancement of hypoxia state. Learning and memory function, improving the effect of hypoxia

Active Publication Date: 2006-06-28
LIAOYUAN YULONG YADONG PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Cerebrovascular diseases mainly include cerebral thrombosis, cerebral embolism, lacunar infarction, cerebral hemorrhage, cerebral arteriosclerosis, etc. The symptoms of these diseases include complete or incomplete and mixed aphasia, limb paralysis, pain or deep sensory disturbance, Dizziness, memory loss, tinnitus, brain function decline and other symptoms, these symptoms have brought great pain to the patient, the current treatment drugs have a low cure rate, can not cure, can only relieve symptoms, and the curative effect is slow

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0044] A compound piracetam cerebroprotein hydrolyzate preparation can be made into tablets, capsules, granules and other clinically acceptable dosage forms.

[0045] The traditional Chinese medicine preparation is formulated according to the following raw materials by weight percentage: 35-70% of piracetam, 25-50% of cerebroprotein hydrolyzate, 2-10% of glutamic acid, 2-10% of chondroitin sulfate, and vitamin B10. 05-0.5%, vitamin B2 0.05-0.5%, vitamin B6 0.03-0.3%, vitamin E 0.3-1.0%.

[0046] Its optimal ratio is: Piracetam 55.05%, cerebroprotein hydrolyzate 33.03%, glutamic acid 5.51%, chondroitin sulfate 5.51%, vitamin B1 0.14%, vitamin B2 0.14%, vitamin B6 0.07%, vitamin E 0.55%.

[0047] Its weight can be weighed as follows: Piracetam 55.05g, cerebroprotein hydrolyzate 33.03g, glutamic acid 5.51g, chondroitin sulfate 5.51g, vitamin B1 0.14g, vitamin B2 0.14g, vitamin B6 0.07g, vitamin E 0.55g.

[0048] The tablets are made in the following way: after mixing the above...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a Piracetam brain proteolytic preparation for treating brain neurological disorders and its preparing process, wherein the preparation comprises the following raw materials (by weight portion), Piracetam 35-70%, brain proteolytic product 25-50%, glutacid 2-10%, chondroitin sulfate 2-10%, vitamin B1 0.05-0.5%, vitamin B2 0.05-0.5%, vitamin B6 0.03-0.3%, and vitamin E 0.3-1.0%.

Description

technical field [0001] The invention relates to a compound preparation for treating brain and central nervous system diseases. The preparation can treat diseases such as aphasia, paralysis, pain or deep sensory disturbance caused by cerebral thrombosis and other cerebrovascular diseases, and can assist in the treatment of infectious and non-infectious diseases of the central nervous system. Diseases such as purulent meningitis, etc., can also assist in the treatment of mental disorders caused by schizophrenia, and can relieve mental disorders such as emotional and passive contact. Background technique [0002] Cerebrovascular diseases mainly include cerebral thrombosis, cerebral embolism, lacunar infarction, cerebral hemorrhage, cerebral arteriosclerosis, etc. The symptoms of these diseases include complete or incomplete and mixed aphasia, limb paralysis, pain or deep sensory disturbance, Symptoms such as trance, memory loss, tinnitus, and brain function decline have brought...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K35/30A61K31/737A61K9/16A61K9/20A61K9/48A61P25/00A61P7/02
Inventor 赵玉龙
Owner LIAOYUAN YULONG YADONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com